Pompe Disease
Conditions
Keywords
Amicus Therapeutics, Duvoglustat, AT2220
Brief summary
The main purpose of this study was to determine the safety and tolerability of 3 different doses of duvoglustat (AT2220) in participants affected by Pompe disease. The study also evaluated the effects of duvoglustat on functional parameters in Pompe disease.
Detailed description
This was a Phase 2, open-label study in participants with Pompe disease, a lysosomal storage disorder. Duvoglustat is designed to act as a pharmacological chaperone of alpha-glucosidase, in order to restore enzyme activity. This study consisted of a 28-day screening period, an 11-week treatment period, and a 1-week follow-up period. Three dosing regimens of oral duvoglustat were to be evaluated (Cohort 1: 2.5 g daily for 3 days, followed by no study drug for 4 days; Cohort 2: 5 g daily for 3 days, followed by no study drug for 4 days; Cohort 3: 5 g daily for 7 days, followed by no study drug for 7 days). Participants meeting all eligibility criteria underwent physical examination, electrocardiogram, spirometry, muscular strength test, functional muscle test, 6-minute walk test (when appropriate), laboratory tests, magnetic resonance imaging, and muscle (needle) biopsy. Quality of life was assessed via the 36-Item Short Form Health Survey questionnaire. Functional ability and level of handicap was assessed by Rotterdam handicap scale.
Interventions
DRUGDuvoglustat
Powder in a bottle for dissolution in water for oral administration
Sponsors
Amicus Therapeutics
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, 18 to 74 years of age inclusive * Diagnosis of Pompe disease based on clinical assessment, enzyme assay, and/or genotyping. Confirmatory genotyping will be performed on all participants who are screened for the study * Naïve to enzyme replacement therapy (ERT) or has not received ERT in the 3 months prior to screening * Willing not to initiate ERT or other prohibited treatment during study participation * Functional grade for arms and/or legs ≥2 OR sitting forced vital capacity ≥30% and \<80% of predicted value, reproducible between screening and baseline (±15%) * Participants of reproductive potential agree to use reliable methods of contraception during the study * Participant or legal representative is willing and able to provide written informed consent
Exclusion criteria
* Any intercurrent condition that may preclude accurate interpretation of study data * Obstructive pulmonary disease * Invasive ventilatory support * Use of noninvasive ventilatory support \>8 hours/day while awake * History of QTc prolongation \>450 milliseconds (msec) for males and \>470 msec for females * History of allergy or sensitivity to the study drug, including any prior serious adverse reaction to iminosugars (such as miglustat or miglitol) * Pregnancy or breast-feeding * Current or recent drug or alcohol abuse * Treatment with another investigational drug within 30 days of study start * Use of prohibited medications ≤3 months prior to screening * Otherwise unsuitable for the study in the opinion of the Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs) | Baseline, Week 11 | The number of participants experiencing severe TEAEs is presented for participants who received duvoglustat treatment in this open-label study. The duration of duvoglustat exposure for Cohort 1 ranged from 2 to 24 days, and their exposure ranged from a total of 7,500 to 32,500 milligrams of duvoglustat. An adverse event (AE) refers to any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation in the clinical study. The following guideline was used to grade the intensity of an AE: mild, the AE is easily tolerated and does not interfere with daily activity; moderate, the AE interferes with the daily activity but the participant is still able to function; severe, the AE is incapacitating and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change In 6-minute Walk Test (6MWT) From Baseline To End Of Study | Baseline, Week 11 | The 6MWT (American Thoracic Society standards) was evaluated in ambulatory participants at screening, baseline, and to the end of the study. It was a standardized test that measured the distance in meters (m) covered over a 6-minute walk. Reference equations used (for 6MWT distance in healthy adults) included: (height in centimeters \[cm\], weight in kilograms \[kg\]) 6MWT distance for men = \[7.57 × height (cm)\] - \[5.02 × age\] - \[1.76 × weight (kg)\] - 309 m; 6MWT distance for women = \[2.11 × height (cm)\] - \[5.78 × age\] - \[2.29 × weight (kg)\] + 667 m |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 Regimen 1: Low-dose duvoglustat (2.5 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks. | 3 |
| Cohort 2 Regimen 1: High-dose duvoglustat (5.0 g) QD for 3 days, followed by no drug for 4 days, for 11 weeks. | 0 |
| Cohort 3 Regimen 2: High-dose duvoglustat (5.0 g) QD for 7 days, followed by no drug for 7 days, for 11 weeks. | 0 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Overall Study | Adverse Event | 2 | 0 | 0 |
| Overall Study | Physician Decision | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Cohort 1 | Total |
|---|---|---|
| Age, Continuous | 49.07 years STANDARD_DEVIATION 11.02 | 49.07 years STANDARD_DEVIATION 11.02 |
| Sex: Female, Male Female | 2 Participants | 2 Participants |
| Sex: Female, Male Male | 1 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — |
| other Total, other adverse events | 3 / 3 | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 2 / 3 | 0 / 0 | 0 / 0 |
Outcome results
Primary
Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs)
The number of participants experiencing severe TEAEs is presented for participants who received duvoglustat treatment in this open-label study. The duration of duvoglustat exposure for Cohort 1 ranged from 2 to 24 days, and their exposure ranged from a total of 7,500 to 32,500 milligrams of duvoglustat. An adverse event (AE) refers to any unfavorable and unintended sign, symptom, syndrome, or illness that develops or worsens during the period of observation in the clinical study. The following guideline was used to grade the intensity of an AE: mild, the AE is easily tolerated and does not interfere with daily activity; moderate, the AE interferes with the daily activity but the participant is still able to function; severe, the AE is incapacitating and requires medical intervention. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline, Week 11
Population: Safety Population: All participants who received at least 1 dose of duvoglustat.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1 | Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events (TEAEs) | 1 Participants |
Secondary
Change In 6-minute Walk Test (6MWT) From Baseline To End Of Study
The 6MWT (American Thoracic Society standards) was evaluated in ambulatory participants at screening, baseline, and to the end of the study. It was a standardized test that measured the distance in meters (m) covered over a 6-minute walk. Reference equations used (for 6MWT distance in healthy adults) included: (height in centimeters \[cm\], weight in kilograms \[kg\]) 6MWT distance for men = \[7.57 × height (cm)\] - \[5.02 × age\] - \[1.76 × weight (kg)\] - 309 m; 6MWT distance for women = \[2.11 × height (cm)\] - \[5.78 × age\] - \[2.29 × weight (kg)\] + 667 m
Time frame: Baseline, Week 11
Population: Safety Population: All participants who received at least 1 dose of duvoglustat.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Cohort 1 | Change In 6-minute Walk Test (6MWT) From Baseline To End Of Study | -19.660 m | Standard Deviation 41.1845 |